Efficiency and toxicity of nab-paclitaxel and camrelizumab in the second or above line treatment of advanced non-small cell lung cancer: a retrospective cohort study

BACKGROUND: Paclitaxel-based chemotherapy represented by nanoparticle albumin-bound paclitaxel (nab-ptx) combined with programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors has become the standard model for the 1(st) treatment of advanced non-small cell lung cancer (NSC...

Descripción completa

Detalles Bibliográficos
Autores principales: Yin, Chen, Zou, Guo-Rong, He, Yan, Li, Juan, Yan, Hao-Wen, Su, Zhen, Cao, Xiao-Long, Li, Xiao-Bing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183515/
https://www.ncbi.nlm.nih.gov/pubmed/37197501
http://dx.doi.org/10.21037/jtd-23-387

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183515/
https://www.ncbi.nlm.nih.gov/pubmed/37197501
http://dx.doi.org/10.21037/jtd-23-387

Ejemplares similares